BREAKING NEWS: Dow Dismisses Friday Rally, Logs Worst Week in 2 Years
Toggle navigation
About Us
Who We Are
About Bernie Schaeffer
Our Newsroom
FAQ
Contact Us
Corrections
Ethics & Fact Checks Policy
Market News
Sign Up for Free Market Newsletters
Opening View
Midday Market Check
Market Recap
View All Free Subscriptions
Schaeffer's Volatility Scorecard
Featured Publication
From the Top
Monday Morning Outlook
Indicator of the Week
Editor's Picks
View All
Trading Analysis
Best & Worst Stocks
Earnings Preview
Investor Sentiment
Quantitative Analysis
Technical Analysis
VIX & Volatility
View All
Stock Options
Intraday Options Activity
Most Active Options
Trade Postmortems
Options Recommendations
View All
Trading Education
Strategies & Concepts
Expectational Analysis
View All
Market News
Buzz Stocks
Stocks on the Move
Analyst Update
5 Minute Market Rundown
Stock Market Podcasts
View All
Daily Market Newsletters
Opening View
Midday Market Check
Market Recap
View All
Trade Alerts
All Trading Services
Most Popular Services
Elite Trader
Quick-Hit Trader
Lightning Trader
Ultimate Trader
View All
Directional Trading
Options Under $5
Leverage
Weekly Options Trader
Event Trader
PowerTrend
Schaeffer's Players
Overnight Trader
View All
Advanced Trading Alerts
Wealthbuilder
Premium Trader
Hedge Hunter
Volatility Trader
Weekly Volatility Trader
View All
Weekend Alert
Weekend Player
Weekend Trader Alert
Expiration Week Countdown
Weekly Options Countdown
View All
Newsletter Trading Services
Master Portfolio
The Option Advisor
Schaeffer's Daily Bulletin
View All
Courses & Education
Getting Started with Options
View All
Options 101
Deals
Deal of the Week
Broker Center
Free Trial
Log-In
Search
content-search-index
Tag: NASDAQ-AIMT
NASDAQ-AIMT
1
SEARCH RESULTS FOR: "Tag: NASDAQ-AIMT"
REFINE YOUR SEARCH
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2018
(1)
CATEGORIES
Buzz Stocks
(1)
Aimmune Therapeutics Stock Nabs Record High After Drug Data
https://www.schaeffersresearch.com/content/news/2018/02/20/aimmune-therapeutics-stock-nabs-record-high-after-drug-data
2/20/2018 10:25 AM
Aimmune Therapeutics Inc (NASDAQ:AIMT) stock is in focus this morning, after the company's peanut allergy drug AR101 met its late-stage study goals. Aimmune will now seek U.S. approval by the end of 2...
LOAD MORE
PEOPLE ALSO SEARCH FOR
NASDAQ-AIMT